Posted by Michael Wonder on 19 Oct 2020
Aimmune receives positive CHMP opinion on Palforzia for the treatment of patients with peanut allergy in Europe
16 October 2020 - Final European Commission Decision on Marketing Approval Anticipated in Q4 2020.
Aimmune Therapeutics, a Nestlé Health Science Company, today announced that the CHMP of the EMA adopted a positive opinion on Palforzia [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergy in peanut allergic patients aged 4 – 17 years in the European Union.
